Skip to main content
Equibles
CBLL logo

CBLL · Ceribell, Inc. · Metrics

Track CBLL — free

Use CBLL with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research CBLL.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$27.00 +0.41 (+1.54%) Play latest call Q3 2026 earnings call transcript
Russell 2000 member Rebalance outlook locked
Market Cap
$1.03B
Shares
38.84M
Volume · Nov 9 34.09K Avg daily vol (3M) 471.63K

CBLL metrics

88 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$26.59
Market cap
$1.03B

Price action

23 metrics
Price change (1W)
+0.0%
Price change (30D)
+12.5%
Price change (3M)
+41.4%
Price change (6M)
+31.6%
Price change (YTD)
+21.2%
Price change (1Y)
+130.0%
Trailing year
Price change (5Y)
—
52-week high
$28.27
52-week low
$11.56
Change from 52-week high
-5.9%
Change from 52-week low
+130.0%
Annualized volatility
51.2%
Annualized volatility (3M)
51.4%
Implied volatility (30D)
60.4%
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
1.1
RSI (14D)
51.9
Price vs SMA 50
+5.3%
Price vs SMA 200
+27.2%
Avg volume (3M)
471,627
Relative volume
0.9
Average dollar volume
$11.82M

Company

3 metrics
Sector
Healthcare
Industry
Medical Devices
Shares outstanding
38.84M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
8.6×
reciprocal yield 11.6%
EV / EBITDA
—
EV / EBIT
—
P / sales
9.5×
reciprocal yield 10.5%
P / book
8.8
reciprocal yield 11.4%
FCF yield
-5.5%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-7.2%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
6.2×
reciprocal yield 16.1%
EV / revenue historical average (5Y)
6.2×
reciprocal yield 16.1%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-11-03

Profitability

9 metrics
Gross margin
89.3%
Operating margin
-69.8%
Trailing 12 months
Net margin
-68.0%
Gross profit (TTM)
$97.04M
Operating profit (TTM)
−$75.87M
Net income (TTM)
−$73.88M
Trailing 12 months
Diluted EPS (TTM)
$-1.93
FCF margin
-51.9%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$2.87
Gross profit per diluted share (TTM)
$2.56
Operating profit per diluted share (TTM)
$-2.00
EBITDA per diluted share (TTM)
$-1.97
Net income per diluted share (TTM)
$-1.95
Operating cash flow per diluted share (TTM)
$-1.48
Free cash flow per diluted share (TTM)
$-1.49
Capital expenditures per diluted share (TTM)
$0.01
R&D per diluted share (TTM)
$0.67
Stock compensation per diluted share (TTM)
$0.53
Book value per share
$4.14

Growth

11 metrics
Revenue growth YoY
+29.9%
Year over year
Net income growth YoY
—
Revenue (TTM)
$108.72M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+4.6%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-62.9%
Return on assets
-47.2%
Debt / equity
0.2
Current ratio
8.2
EBITDA (TTM)
−$74.72M
Free cash flow (TTM)
−$56.43M
Quick ratio
7.8
Interest coverage
-47.4
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$97.47M
Latest balance sheet
Cash & equivalents
$41.99M
Total assets
$156.37M
Total debt
$20.00M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$56.01M
Capital expenditures (TTM)
$421,000
R&D (TTM)
$25.37M
SG&A (TTM)
—
Stock compensation (TTM)
$20.18M
R&D / revenue
23.3%
Stock compensation / revenue
18.6%

Ownership (13F)

9 metrics
13F filers
122
13F filer change QoQ
0
Institutional ownership
78.6%
Conviction holders (share of 13F filers)
4.1%
Crowding (high-turnover and private-fund holders)
22.7%
Private-fund adviser ownership
21.1%
Active holders' share change QoQ
+4.5%
Holder tenure
5.9
Price vs estimated holder cost
-12.5%

Ownership (registered funds)

1 metrics
Index-fund ownership
8.8%

Short interest

3 metrics
Short interest
5.6%
Latest settlement · 4.8 days to cover
Days to cover
4.8d
Short-squeeze score
75 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$4.44M
Insider-sentiment score
20 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1861107 CUSIP 15678C102 13F (30d) 41 filings 40 filers Visit website Investor relations